Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 2/20 | 0.60 |
| ▸ | BTK | Q06187 | 9/20 | 0.46 |
| ▸ | FGFR4 | P22455 | 7/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.44 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18345263 | 1.00 | TNK2 (0.60) | TNK2BTKFGFR4FGFR1FGFR3 | |
| SCHEMBL18099743 | 0.91 | TNK2 (0.58) | TNK2BTKFGFR4FGFR1FGFR3 | |
| SCHEMBL18099747 | 0.89 | TNK2 (0.61) | TNK2BTKFGFR4FGFR1FGFR3 | |
| SCHEMBL20962359 | 0.89 | BTK (0.51) | TNK2BTKFGFR4FGFR1FGFR3 | |
| SCHEMBL16748868 | 0.89 | TNK2 (0.51) | TNK2BTKHPGDS | |
| SCHEMBL28633843 | 0.89 | TNK2 (0.60) | TNK2BTKFGFR4FGFR1FGFR3 | |
| SCHEMBL28643796 | 0.89 | TNK2 (0.60) | TNK2BTKFGFR4FGFR1FGFR3 | |
| SCHEMBL18345372 | 0.89 | TNK2 (0.51) | TNK2BTKHPGDS | |
| SCHEMBL20962382 | 0.87 | TNK2 (0.46) | TNK2BTKFGFR4FGFR1FGFR3 | |
| SCHEMBL20962197 | 0.87 | BTK (0.49) | TNK2BTKFGFR4FGFR1FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3313839-A1 | TYROSINE KINASE INHIBITORS | Principia Biopharma Inc. (US) | 2018-05-02 | — | — | EP | disclosed |
| US-9822120-B2 | Protein kinase inhibitors | PHARMASCIENCE INC. (CA) | 2017-11-21 | — | — | US | disclosed |
| WO-2016210165-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2016-12-29 | — | — | WO | disclosed |
| US-20160280711-A1 | Protein Kinase Inhibitors | PHARMASCIENCE INC. (CA) | 2016-09-29 | — | — | US | disclosed |
| WO-2015074138-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE INC. (CA) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280711-A1 | Protein Kinase Inhibitors | TEC, LCK, SRC | TNK2 43/4885BTK 8/4885FGFR4 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.